Abstract
Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis and liver cancer worldwide. Adaptive mutations play important roles in the development of the HCV replicon and its infectious clones. We and others have previously identified the p7 mutation F772S and the co-presence of NS4A mutations in infectious HCV full-length clones and chimeric recombinants. However, the underlying mechanism of F772S function remains incompletely understood. Here, we investigated the functional role of F772S using an efficient JFH1-based reporter virus with Core-NS2 from genotype 2a strain J6, and we designated J6-p7/JFH1-4A according to the strain origin of the p7 and NS4A sequences. We found that replacing JFH1-4A with J6-4A (wild-type or mutated NS4A) or genotype 2b J8-4A severely attenuated the viability of J6-p7/JFH1-4A. However, passage-recovered viruses that contained J6-p7 all acquired F772S. Introduction of F772S efficiently rescued the viral spread and infectivity titers of J6-p7/J6-4A, which reached the levels of the original J6-p7/JFH1-4A and led to a concomitant increase in RNA replication, assembly and release of viruses with J6-specific p7 and NS4A. These data suggest that an isolate-specific cooperation existed between p7 and NS4A. NS4A exchange- or substitution-mediated viral attenuation was attributed to the RNA sequence, and no p7-NS4A protein interaction was detected. Moreover, we found that F772S-enhanced p7-NS4A cooperation was associated with the enlargement of intracellular lipid droplets. This study therefore provides new insights into the mechanisms of adaptive mutations and facilitates studies on the HCV life cycle and virus–host interaction.
Highlights
Introduction HepatitisC virus (HCV) chronically infects 71 million people worldwide according to the estimation of World Health Organization[1]
We demonstrated that p7 cooperated with NS4A in an isolate-specific manner
Mutation F772S compensated for the viral attenuation that resulted from NS4A replacement, implying a p7-NS4A
Summary
C virus (HCV) chronically infects 71 million people worldwide according to the estimation of World Health Organization[1]. HCV infection can lead to chronic hepatitis C, which increases the risk of developing liver fibrosis, cirrhosis, and hepatocellular carcinoma[2,3]. The use of direct-acting antiviral agents (DAAs) has revolutionized HCV therapy and cured ≥ 90% of patients[4]. Pegylated interferon-α in combination with ribavirin (Peg-IFN/RBV) is still the standard of care for hepatitis C in many countries and/or regions[5], which has unfavorable adverse effects and only cures ~50% of patients[6].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.